97 related articles for article (PubMed ID: 6235158)
1. Changes in apolipoprotein AI after treatment with high-dose medroxyprogesterone acetate.
Crona N; Enk L; Friberg LG; Samsioe G; Silfverstolpe G
Gynecol Obstet Invest; 1984; 18(1):16-20. PubMed ID: 6235158
[TBL] [Abstract][Full Text] [Related]
2. A prospective, one-year study on the effects of two long acting injectable contraceptives (depot-medroxyprogesterone acetate and norethisterone oenanthate) on serum and lipoprotein lipids.
Enk L; Landgren BM; Lindberg UB; Silfverstolpe G; Crona N
Horm Metab Res; 1992 Feb; 24(2):85-9. PubMed ID: 1533383
[TBL] [Abstract][Full Text] [Related]
3. High-dose depot-medroxyprogesterone acetate (DMPA) - effects on lipid and lipoprotein metabolism.
Crona N; Enk L; Samsioe G; Silfverstolpe G; Skryten A
Eur J Obstet Gynecol Reprod Biol; 1983 Oct; 16(2):97-105. PubMed ID: 6227506
[TBL] [Abstract][Full Text] [Related]
4. [Injectable contraceptive, DMPA, serum HDL cholesterol and heart infarct].
Kremer J; de Bruijn HW; Hindriks FR
Ned Tijdschr Geneeskd; 1981 Aug; 125(35):1418-21. PubMed ID: 6456421
[TBL] [Abstract][Full Text] [Related]
5. Medroxyprogesterone acetate and lipid metabolic changes.
Teichmann AT; Wander HE; Cremer P; Wieland H; Kuhn W; Nagel GA; Seidel D
Arzneimittelforschung; 1987 May; 37(5):573-7. PubMed ID: 2956958
[TBL] [Abstract][Full Text] [Related]
6. The Food and Drug Administration and medroxyprogesterone acetate. What are the issues?
Rosenfield A; Maine D; Rochat R; Shelton J; Hatcher RA
JAMA; 1983 Jun; 249(21):2922-8. PubMed ID: 6221125
[TBL] [Abstract][Full Text] [Related]
7. Depot-medroxyprogesterone acetate (DMPA) and risk of endometrial cancer. The WHO Collaborative Study of Neoplasia and Steroid Contraceptives.
Int J Cancer; 1991 Sep; 49(2):186-90. PubMed ID: 1831802
[TBL] [Abstract][Full Text] [Related]
8. High-dose depot-medroxyprogesterone acetate--effects on the fatty acid composition of serum lecithin and cholesterol ester.
Enk L; Crona N; Friberg LG; Samsioe G; Silfverstolpe G
Gynecol Oncol; 1985 Nov; 22(3):317-23. PubMed ID: 2933308
[TBL] [Abstract][Full Text] [Related]
9. High density lipoprotein cholesterol and apolipoprotein A-I levels in 32-33-year-old women on steroid contraceptives-differences between two frequently used low-estrogen pills.
Havekes L; van Gent CM; Stegerhoek CI; Arntzenius AC; Hessel LW
Clin Chim Acta; 1981 Oct; 116(2):223-9. PubMed ID: 6457706
[TBL] [Abstract][Full Text] [Related]
10. [Adjuvant hormone therapy in endometrial carcinoma: medroxyprogesterone acetate versus tamoxifen-medroxyprogesterone acetate sequential therapy].
Vavra N; Salzer H; Sevelda P; Breitenecker G; Czerwenka K; Kucera H
Gynakol Rundsch; 1990; 30(3):133-43. PubMed ID: 2147161
[TBL] [Abstract][Full Text] [Related]
11. Comparison of mass spectrometry and radioimmunoassay to measure medroxyprogesterone acetate in patients with endometrial cancer.
Kärkkäinen J; Vesterinen E; Stenman UH; Adlercreutz H; Nieminen U; Widholm O
Eur J Cancer; 1990; 26(9):975-7. PubMed ID: 2149024
[TBL] [Abstract][Full Text] [Related]
12. [Effect of conjugated estrogen and Org OD14 on serum lipoprotein and apolipoprotein in perimenopausal and postmenopausal women].
Bai W; Yang X; Zheng S
Zhonghua Fu Chan Ke Za Zhi; 1999 May; 34(5):293-6. PubMed ID: 11326938
[TBL] [Abstract][Full Text] [Related]
13. [Progesterone receptors in endometrial carcinoma and their response to medroxyprogesterone acetate].
Feng YJ; Zhang XY
Zhonghua Fu Chan Ke Za Zhi; 1989 May; 24(3):153-5, 189. PubMed ID: 2530067
[TBL] [Abstract][Full Text] [Related]
14. Cardiovascular Disease Risk Associated With the Long-term Use of Depot Medroxyprogesterone Acetate.
Dilshad H; Yousuf RI; Shoaib MH; Jamil S; Khatoon H
Am J Med Sci; 2016 Nov; 352(5):487-492. PubMed ID: 27865296
[TBL] [Abstract][Full Text] [Related]
15. [The medroxyprogesterone acetate serum level following various medroxyprogesterone acetate dose schedules in gynecologic oncology].
Husslein P; Egarter C; Eppel W; Salzer H; Spona J
Zentralbl Gynakol; 1988; 110(20):1277-82. PubMed ID: 2977043
[TBL] [Abstract][Full Text] [Related]
16. [Results of the use of chlormadinone and farlutal depot in hormonal therapy of uterine cancer].
Witczak-Ploch E
Nowotwory; 1983; 33(2):129-38. PubMed ID: 6198636
[No Abstract] [Full Text] [Related]
17. WHO special programme of research, development and research training in human reproduction. Task force on long-acting agents for the regulation of fertility.
Contraception; 1982 Jan; 25(1):1-11. PubMed ID: 6460593
[TBL] [Abstract][Full Text] [Related]
18. [Conservative surgery combined with depot medroxyprogesterone acetate in treatment of moderate or severe endometriosis].
Zhou J; Lei ZW; Lü JQ; Sun J; Xu XW
Zhonghua Fu Chan Ke Za Zhi; 2005 Jan; 40(1):5-8. PubMed ID: 15774083
[TBL] [Abstract][Full Text] [Related]
19. Continuous, high-dose progestogen treatment of endometrial cancer.
Szarvas Z; Zsolnai B; Gimes G; Hidvégi J
Gynecol Obstet Invest; 1987; 24(4):262-6. PubMed ID: 2962910
[TBL] [Abstract][Full Text] [Related]
20. International forum update: depot medroxyprogesterone acetate and endometrial carcinoma.
McDaniel EB; Potts M
Int J Gynaecol Obstet; 1979; 17(3):297-9. PubMed ID: 42591
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
